JP Morgan maintains Sotera Health at Underweight, lowers price target to $15 from $17

JP Morgan kept Sotera Health at Underweight, reducing its price target to $15 from $17, citing an 11.8% decrease. This implies a 6.4% downside from the Nov 3 close of $16.03.

Original reporting
Published Nov 4, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan maintains Sotera Health at Underweight, lowers price target to $15 from $17 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The downgrade reflects JP Morgan's revised outlook, potentially prompting traders to reduce long positions.

02

Market read

The new target suggests a near-term downside for SOTR, relevant for traders with exposure to biotech microcaps.

03

What to watch

Potential upcoming clinical trial data or partnership announcements could offset the target cut.

Relevance 7/10Novelty 8/10Timing: today

Background

Analyst price target adjustments are a common catalyst for short-term stock moves.

Market effects

Healthcare sector may face slight downside pressure from the downgrade.

US market participants may adjust exposure to small-cap biotech stocks.

Limited to investors tracking US-listed biotech equities.

Counterpoint

If the broader market remains bullish on biotech, the downgrade may be a temporary overreaction.

Key entities

  • Sotera Health

    US-listed biotech firm (NASDAQ: SOTR).

  • JP Morgan

    Investment bank providing the price target revision.

Related articles

MedAI 8/10

Sotera Health Company Q3 2026 Earnings Call Summary

Sotera Health reported Q3 2026 earnings, with Sterigenics and Nelson Labs driving performance. Nordion saw revenue decline due to cobalt-60 timing. Management noted European market softness. Guidance reaffirmed, with flat Q4 Sterigenics revenue and reduced 2027 CapEx. Nelson Labs' growth expected to moderate. Net leverage improved to 2.9x, leading to a credit rating upgrade. Litigation and FX headwinds noted.

$SHCHighAI 8/10

Sotera Health (SHC) Q3 2026 Earnings Call Transcript

Sotera Health (SHC) reported Q3 2026 revenue growth of 4.4% to $325M and adjusted EBITDA growth of 4% to $171M. Sterigenics grew 8.2%, Nelson Labs 9.2%, and Nordion declined 11.5%. The company reaffirmed its 2026 revenue and adjusted EBITDA outlook, expecting 5.25-6.75% and 5.75-7.25% growth, respectively. Adjusted EBITDA margins expanded sequentially by 100 basis points to 52.5%.

$SHCHighAI 8/10

Why is Sotera Health stock sliding today?

Sotera Health (SHC) shares fell 9.5% despite Q3 2026 earnings beat (EPS $0.29, revenue $324.9M) due to cautious guidance. Revenue declined 12% in the Nordion segment. JPMorgan downgraded to Underweight with a $17 target, and insiders sold 1.29M shares. The S&P 500 and Nasdaq rose, but Sotera's decline was company-specific.

$SHCMed

What Sotera Health (SHC) Said on Its Q3 Earnings Call

Sotera Health (SHC) reported Q3 earnings, noting softness in the European medical-device market. Sterigenics expects 6% constant-currency growth in Q4, while Nelson Labs saw 8.8% revenue growth. Nordion revenue fell 12.4% due to shipment timing. The company reaffirmed its 2026 outlook for 5.25% to 6.75% revenue growth and maintained its adjusted EBITDA forecast.